id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-312125-j9l6l3dx	Pau, Alice K.	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel	2020-09-25		.txt	text/plain	1800	74	42	Given the lack of data from properly powered RCTs, and the need to inform regulatory decision making regarding continued access to convalescent plasma, both the FDA and the Mayo Clinic performed retrospective, indirect evaluations of efficacy by using EAP data, hypothesizing that patients who received plasma units with higher titers of neutralizing antibodies would have better clinical outcomes. Ann Intern Med DOI: 10.7326/m20-6448 sha: doc_id: 312125 cord_uid: j9l6l3dx In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials.	cache/cord-312125-j9l6l3dx.txt	txt/cord-312125-j9l6l3dx.txt
